Peggy E. McCann
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Receptor Mechanisms and Signaling, Diabetes, Cardiovascular Risks, and Lipoproteins, Adipokines, Inflammation, and Metabolic Diseases, Neuropeptides and Animal Physiology
Most-Cited Works
- → Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes(2012)86 cited
- → Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists(2005)40 cited
- → A new class of glycogen phosphorylase inhibitors(2003)35 cited
- → Anthranilic acid replacements in a niacin receptor agonist(2010)19 cited
- → Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia(2009)13 cited
- → Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality(2023)7 cited